Solid Organ Transplant (SOT) Market

Solid Organ Transplant (SOT) Market Outlook (2024 to 2034)

The global solid organ transplant (SOT) market is estimated at US$ 4.9 billion in 2024 and has been forecasted to increase at a CAGR of 4.9% to reach US$ 7.88 billion by the end of 2034.

Since early ages, people have faced problems in their organs that are sometimes fatal and can lead to death. As a result, transplantation techniques were introduced as technology advanced, and the emergence of solid organ transplants has taken things a step further. Growing requirements for these procedures and the introduction of new and more efficient techniques are driving overall solid organ transplant market growth.

• In the United Kingdom, the National Health Service is carrying out regular public awareness to make people understand and encourage them to register for organ donations. These programs are increasing the popularity of organ donations across the country.
• In the year 2022, a fundraising event was organized by the American Transplant Foundation. This program advertised and promoted public awareness related to various organ donations and transplantation.
• In the Middle East and Africa region, the market is showing potential to progress at a CAGR of 4.8%, which is even higher than in Eastern Europe. This has allowed research organizations to expand their business in this region.

Report Attributes	Details
Solid Organ Transplant (SOT) Market Size (2024E)	US$ 4.9 Billion
Forecasted Market Value (2034F)	US$ 7.88 Billion
Global Market Growth Rate (2024 to 2034)	4.9% CAGR
East Asia Market Share (2024E)	13.7%
North America Market Growth Rate (2024 to 2034)	5.8% CAGR
Alkylating Agents Segment Value (2034F)	268.2 Million
mTOR Inhibitors Segment Value (2034F)	US$ 1.26 Billion
Key Companies Profiled	Astellas Pharma US, Inc.; Bristol-Myers Squibb Company; AbbVie Inc.; Amneal Pharmaceuticals, Inc.; Asahi Kasei Pharma Corporation; Azurity Pharmaceuticals, Inc.; Bausch Health Companies Inc.; Genentech USA, Inc.; Glenmark Pharmaceuticals Inc., USA; Novartis; Pfizer Inc.; Sanofi S.A.; F. Hoffmann-La Roche AG

Why is the Solid Organ Transplant Market Size Expanding at a Steady Rate?

“Huge Waiting List of Organ Recipients”

One of the primary drivers that are helping research organizations and hospitals make huge profits is the significant increase in transplantation procedures around the world. More people are indulging in poor lifestyle choices such as drinking and smoking, even though they are aware of their ill effects. These poor lifestyle choices have increased the incidence of organ failure and other health issues. Chronic illnesses, including cancer, kidney failure, COPD, and lupus, often result in damage to tissues and organs.

Several governments are focusing on increasing awareness about the benefits of organ donation, which can help people who are in need since the lack of organs is a key concern.

“Introduction of 3D-Printed Organs”

Advent of 3D printers has opened a new gate of possibilities in the medical field. Printing of organs has now become a real possibility, and this is a big help when there are no organ donors available when needed. An emerging technology in 3D tissue products is autologous stem cell transplant, which has become popular due to the introduction of induced pluripotent stem cells. Doctors and scientists alike are looking to develop organs from human-induced pluripotent stem cells.

• BioFibr, known for its innovative technological products, launched a bio-ink additive in June 2023, called μCollaFibR and CollaFibR 3D scaffold. This new fiber product is becoming common in the bioprinting of tissue and organ models.

Country-wise Analysis

Health issues are somewhat global and every country is trying its best to advance its healthcare system. The United States, Canada, Eastern Europe, Western Europe, and South Korea and some of the key markets in this landscape. East Asia and North America are foreseen to hold significant solid organ transplant market shares over the next ten years.

What is Becoming a Success Factor for Healthcare Professionals in India?

“Private and Public Institutions Coming Together to Reduce Waiting Period”

Attribute	India
Market Value (2024E)	US$ 243.6 Million
Growth Rate (2024 to 2034)	7% CAGR
Projected Value (2034F)	US$ 478.2 Million

India is a developing country and it becomes very important for the government to keep a close connection with private institutions to solve major issues to become a strong and developed country. The government in India has identified how the prolonged waiting time can lead to a severe loss of both money and life. It has introduced various programs where common people are made aware of organ donations on a large scale. More people are understanding the importance of this and how they can save the lives of fellow citizens. As a result, the waiting time for patients has reduced significantly, though much more needs to be done over the coming years.

• The National Organ Transplant Programme (NOTP) is a program by the Government of India that aims to promote organ donation and transplantation across the country, which was introduced in the year 2021.

What is the Market Situation for Solid Organ Transplants in the United States?

“Implementation of Telemedicine and AI integration”

Attribute	United States
Market Value (2024E)	US$ 1.74 Billion
Growth Rate (2024 to 2034)	5.6% CAGR
Projected Value (2034F)	US$ 3 Billion

The United States is always known for its early technological moves in many fields, including healthcare. The country has understood the potential of AI and is figuring out how it can improve surgical procedures and therapies to decrease the recovery time of patients. Key healthcare professionals in the country have also started to use telemedicine, which is a technique to enable remote patient evaluation, enhancing access to transplant services, especially for those in remote areas or accident spots. This is widening the market possibilities for solid organ transplants across the whole country.

Category-wise Examination

The market has been segmented into various categories according to therapies and drugs involved in the healing process. These include drug class, therapy type, and distribution channels.

Which Type of Therapy is Preferred for Solid Organ Transplants?

“Targeted Immunosuppressive Therapy More Desirable Compared to Other Therapies”

Attribute	Targeted Immunosuppressive Therapy
Segment Value (2024E)	US$ 2.71 Billion
Growth Rate (2024 to 2034)	4.7% CAGR
Projected Value (2034F)	US$ 4.29 Billion

Patients are increasingly favoring targeted immunosuppressive therapies over other treatments for solid organ transplants. This preference stems from the potential benefits and improved outcomes associated with targeted immunosuppressive therapies, making them more desirable compared to traditional options. Professional institutions are hiring doctors who have a specialty in these therapies to attract more patients to their hospitals, leading to steady growth in profits.

Which Drugs are Proven to Be More Effective During Recovery?

“Calcineurin Inhibitors Highly Effective in Treatment and Recovery”

Attribute	Calcineurin Inhibitors
Segment Value (2024E)	US$ 1.81 Billion
Growth Rate (2024 to 2034)	5.4% CAGR
Projected Value (2034F)	US$ 3.06 Billion

Calcineurin inhibitors have demonstrated their effectiveness and have gained popularity among patients during organ transplantation recovery. These inhibitors are highly favored by patients due to their ability to effectively facilitate the healing process, thereby contributing to better recovery outcomes and patient satisfaction. This is a key solid organ transplant market trend that is here to stay for many more years to come.

Competitive Landscape

Key players in the solid organ transplant market are also focusing on introducing new products, including artificial eyes and artificial kidneys.

• TransMedics, to expand its business base, acquired Bridge to Life Ltd in August 2023 for technologies, including the LifeCradle Heart Preservation Transport System. This purchase will expand its product offering for organ transplants, making the company stronger in the market
• MediGO and LiveonNY, two big medical firms collaborated in March 2023 and introduced a real-time organ tracking technology. This technology helps in keeping track of organ donations and transplantation.
• In July 2022, Precise Bio and Carl Zeiss came together to work and develop commercialized fabricated corneal tissue for patients in their hospitals and natural lenticular transplants to treat keratoconus and vision correction.

Fact.MR provides detailed information about the price points of prominent players in the solid organ transplant market positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new market report.

Segmentation of SOT Market Research

• By Therapy:

  • Immunomodeulatory Therapies
  • Biomarket-Driven Therapies
  • Targeted Immunosuppressive Therapies

• By Drug Class:

  • Alkylating Agents
  • Calcineurin Inhibitors
  • Interleukin Inhibitors
  • mTOR Inhibitors
  • Antiproliferative Agents
  • Steroids
  • Other Drug Class

• By Organ Type:

  • Kidneys
  • Liver
  • Pancreas
  • Heart
  • Lungs
  • Small Bowel
  • Other Solid Organs

• By Age Group:

  • Infants/Pediatrics
  • Adults

• By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

• By End User:

  • Hospitals
  • Transplant Centres
  • Ambulatory Surgical Centres
  • Academic & Research Centres

• By Region:

  • North America
  • Western Europe
  • Eastern Europe
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa